Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06856525 · ClinicalTrials.gov registry record · Phase 2
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
A Phase 2 study of Electronic Cigarette Related Lung Damage, sponsored by Y. Michael Shim, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06856525 is a Phase 2 study of Electronic Cigarette Related Lung Damage that is actively recruiting participants, run by Y. Michael Shim, MD. The registered enrollment target is 80 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06856525, a Phase 2 study of Electronic Cigarette Related Lung Damage, is actively recruiting participants, sponsored by Y. Michael Shim, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of electronic cigarette use on pulmonary gas exchange capacity and then corroborate the Hyperpolarized Xenon MRI (HXeMRI) results with the cardiopulmonary stress test at the initial visit and a follow-up visit 12 months later.
Conditions Studied
Interventions
- DRUG Hyperpolarized xenon 129
- DIAGNOSTIC_TEST Cardiopulmonary Stress Test
- DIAGNOSTIC_TEST Pulmonary Function Test
- DIAGNOSTIC_TEST Chest CT
Study Locations (2)
North Carolina
- Duke University - Durham
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06856525
The ClinicalTrials.gov registry entry for NCT06856525 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y. Michael Shim, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Electronic Cigarette Related Lung Damage appearing as the primary indexed condition, and to 4 interventions - of which Hyperpolarized xenon 129 is the first listed.
NCT06856525 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT06856525 about?
NCT06856525 is a clinical study titled "Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology". A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of electronic cigarette use on pulmonary gas exchange capacity and then corroborate the Hyperpolarized Xenon...
What is the current status of trial NCT06856525?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-12-19. Estimated completion is 2032-12-31.
What conditions does trial NCT06856525 study?
This clinical trial studies the following conditions: Electronic Cigarette Related Lung Damage.
What interventions are being tested in trial NCT06856525?
The interventions under investigation include: Hyperpolarized xenon 129 (DRUG), Cardiopulmonary Stress Test (DIAGNOSTIC_TEST), Pulmonary Function Test (DIAGNOSTIC_TEST), Chest CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06856525?
This trial is sponsored by Y. Michael Shim, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06856525 being conducted?
This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.